Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Kerr

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|February 1, 2024
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysisAnja L Frei, Anthony McGuigan, Ritik R A K Sinha, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Journal of the National Cancer Institute|August 18, 2021
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT DatabaseZhaohui Jin, Jesse G Dixon, Jack M Fiskum, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker studyEnric Domingo, Luke Freeman-Mills, Emily Rayner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
Scientific Reports|August 4, 2015
Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerNada A Al-Tassan, Nicola Whiffin, Fay J Hosking, et al.
Scientific Reports|May 21, 2015
A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerNada A Al-Tassan, Nicola Whiffin, Fay J Hosking, et al.
Lancet (London, England)|June 1, 2020
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyLennard Yw Lee, Jean-Baptiste Cazier, Vasileios Angelis, et al.
The Lancet. Oncology|August 28, 2020
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyLennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|February 1, 2024
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysisAnja L Frei, Anthony McGuigan, Ritik R A K Sinha, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Journal of the National Cancer Institute|August 18, 2021
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT DatabaseZhaohui Jin, Jesse G Dixon, Jack M Fiskum, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker studyEnric Domingo, Luke Freeman-Mills, Emily Rayner, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
Scientific Reports|August 4, 2015
Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerNada A Al-Tassan, Nicola Whiffin, Fay J Hosking, et al.
Scientific Reports|May 21, 2015
A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerNada A Al-Tassan, Nicola Whiffin, Fay J Hosking, et al.
Lancet (London, England)|June 1, 2020
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyLennard Yw Lee, Jean-Baptiste Cazier, Vasileios Angelis, et al.
The Lancet. Oncology|August 28, 2020
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyLennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, et al.
Pageof 6